Cargando…

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertoli, Sarah, Sterin, Arthur, Tavitian, Suzanne, Oberic, Lucie, Ysebaert, Loïc, Bouabdallah, Reda, Vergez, François, Sarry, Audrey, Bérard, Emilie, Huguet, Françoise, Laurent, Guy, Prébet, Thomas, Vey, Norbert, Récher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349887/ https://www.ncbi.nlm.nih.gov/pubmed/27852053 http://dx.doi.org/10.18632/oncotarget.13262

Ejemplares similares

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
por: Guenounou, Sarah, et al.
Publicado: (2016)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
por: Tavitian, Suzanne, et al.
Publicado: (2015)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients
por: Protin, Caroline, et al.
Publicado: (2019)

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
por: Berger, Eloïse, et al.
Publicado: (2019)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient
por: Beziat, Guillaume, et al.
Publicado: (2019)

A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
por: Beziat, Guillaume, et al.
Publicado: (2022)

Sustained degradation of quality of life in a subgroup of lymphoma survivors: a two-year prospective survey
por: Compaci, Gisèle, et al.
Publicado: (2019)

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Do not jump to hasty conclusions: all gamma delta T-cells neoplasms are not aggressive!
por: Vergez, François, et al.
Publicado: (2019)

Venetoclax with high‐dose methotrexate and rituximab seem effective and well‐tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report
por: Beziat, Guillaume, et al.
Publicado: (2020)

Diagnosis of enteropathy‐associated T‐cell lymphoma (EATL) on peripheral blood: A pleiomorphic morphology and an unusual immunophenotype
por: Ousset, Léa, et al.
Publicado: (2023)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
por: Saland, E, et al.
Publicado: (2015)

Spectrum of Kidney Disorders Associated with T-Cell Immunoclones
por: Piedrafita, Alexis, et al.
Publicado: (2022)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia
por: Cerella, C, et al.
Publicado: (2017)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
por: Vey, Norbert, et al.
Publicado: (2016)

Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
por: Malard, Florent, et al.
Publicado: (2021)

Insights into novel emerging epigenetic drugs in myeloid malignancies
por: Chandhok, Namrata S., et al.
Publicado: (2019)

Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia
por: Larrue, Clément, et al.
Publicado: (2019)

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
por: Vey, Norbert
Publicado: (2020)

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
por: Le Roy, Aude, et al.
Publicado: (2018)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4fhs7j8lg3kod55h2t96dh6mb